Department of Ophthalmology, Trakya University Faculty of Medicine, Edirne, Turkey.
Cutan Ocul Toxicol. 2021 Jun;40(2):85-94. doi: 10.1080/15569527.2021.1902341. Epub 2021 Mar 27.
To investigate the corneal epithelial and limbal epithelial alterations in patients under topical glaucoma treatment using anterior segment-OCT (AS-OCT) and to determine the changes of the limbal region due to the preservatives and glaucoma drugs, that can progress to limbal stem cell deficiency (LSCD). Limbal thickness was measured by AS-OCT to evaluate limbal cell deficiency.
Forty-seven patients using topical medication for glaucoma, and 48 control subjects were enrolled in this matched case-control study. The patients were divided into four groups according to the treatment regimens. Group 1: One-drug regimen, Group 2: Two-drug regimen, Group 3: Three-drug regimen, Group 4: Four-drug regimen For the ocular surface evaluation; tear break-up time with standard fluorescein sodium sterile strip application, Schirmer test-I, Ocular Surface Disease Index Questionnaire, and AS-OCT were performed.
A total of 95 subjects were included: 47 eyes of 47 patients with glaucoma medication and 48 eyes of 48 healthy subjects. There was a statistically significant difference between patients and controls according to BUT, SCH, and OSDI ( < 0.001). The mean central corneal epithelium thickness was 48.5 ± 5.3 in patients and 54.5 ± 5.9 in controls ( < 0.001). The mean central total corneal thickness was 529.2 ± 41.2 in patients and 536 ± 35.3 in controls ( = 0.335). The mean limbal epithelium thickness was 64.1 ± 9.1 in patients and 76 ± 11.5 in controls ( < 0.001).
Using at least one glaucoma drug caused limbal area injury, changed ocular surface measurements, and significantly reduced the limbal epithelial thickness where the stem cells reside. The limbal epithelial thickness measurement by AS-OCT seems to be an innovative, non-invasive, and promising technique for detecting and staging corneal damage in topical glaucoma therapy.
通过眼前段光学相干断层扫描(AS-OCT)研究局部使用青光眼药物治疗患者的角膜上皮和缘部上皮改变,并确定由于防腐剂和青光眼药物引起的缘部区域变化,这些变化可能进展为缘部干细胞缺乏症(LSCD)。通过 AS-OCT 测量缘厚度来评估缘细胞缺乏症。
本病例对照研究纳入了 47 名局部使用青光眼药物治疗的患者和 48 名对照受试者。根据治疗方案将患者分为四组。第 1 组:单药治疗组,第 2 组:两药治疗组,第 3 组:三药治疗组,第 4 组:四药治疗组。进行眼部表面评估;使用标准荧光素钠无菌条进行泪膜破裂时间(BUT)、Schirmer 试验-I、眼表疾病指数问卷(OSDI)和 AS-OCT 检查。
共纳入 95 名受试者:47 例青光眼患者的 47 只眼和 48 名健康受试者的 48 只眼。根据 BUT、SCH 和 OSDI,患者与对照组之间存在统计学显著差异( < 0.001)。患者的中央角膜上皮平均厚度为 48.5 ± 5.3μm,对照组为 54.5 ± 5.9μm( < 0.001)。患者的中央总角膜厚度平均为 529.2 ± 41.2μm,对照组为 536 ± 35.3μm( = 0.335)。患者的中央缘上皮平均厚度为 64.1 ± 9.1μm,对照组为 76 ± 11.5μm( < 0.001)。
使用至少一种青光眼药物会导致缘区域损伤,改变眼表面测量值,并显著降低干细胞所在的缘上皮厚度。AS-OCT 测量缘上皮厚度似乎是一种创新的、非侵入性的、有前途的技术,可用于检测和分期局部使用青光眼治疗中的角膜损伤。